Enhancing super-enhancers

With a new injection of cash, Syros Pharmaceuticals Inc. plans to move its lead cancer program into the clinic, continue to build out its super-enhancer platform technology and expand its discovery engine into other therapeutic areas.

Syros is creating maps of a class of regulatory DNA regions called super-enhancers - master switches responsible for maintaining cell identity - to identify novel targets. The maps are generated by comparing which super-enhancers are active in healthy cells vs. diseased cells...